FTC says patent bat­tle over Parkin­son's drug could have 'sig­nif­i­cant im­pli­ca­tion­s' for pa­tients

The Fed­er­al Trade Com­mis­sion has got­ten in­volved in a patent feud over Su­per­nus’ Parkin­son’s drug Apokyn, a case the agency said may have ‘‘sig­nif­i­cant im­pli­ca­tions” …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA